Bone marrow transplantation following combination chemotherapy immunosuppression (B.A.C.T.) in patients with acute leukemia

R. G. Graw, H. P. Lohrmann, M. I. Bull, J. Decter, G. P. Herzig, J. M. Bull, B. G. Leventhal, R. A. Yankee, R. H. Herzig, G. R. Krueger, W. A. Bleyer, M. L. Buja, M. H. McGinniss, H. J. Alter, J. Whang-Peng, H. R. Gralnick, C. H. Kirkpatrick, E. S. Henderson

研究成果: 雜誌貢獻文章

37 引文 (Scopus)

摘要

HL A and mixed lymphocyte culture identical sibling bone marrow can be engrafted following cyclophosphamide, total body irradiation and B.A.C.T. chemotherapy (4 day cyclophosphamide regimen in combination with 2 agents considered to be effective for treatment of acute myelocytic leukemia, cytosine arabinoside and 6 thioguanine, together with a fourth drug, bis chlorethyl nitrosurea). HL A identical bone marrow can be engrafted across the ABO erythrocyte antigen barrier. B.A.C.T. appears to provide better tumor ablation prior to marrow transplantation and sufficient immunosuppression to produce complete donor chimerism, as compared to cyclophosphamide alone. The 6 day version of the protocol may produce undesirable side effects attributable to the additional cyclophosphamide employed. Current studies in progress will examine the efficacy of the 4 day B.A.C.T. regimen in conjunction with posttransplant treatment with methotrexate for the prevention of graft vs. host disease. In situations where clinically severe graft vs. host disease occurs, patients are treated with antilymphocyte serum.
原文英語
頁(從 - 到)349-354
頁數6
期刊Transplantation Proceedings
6
發行號4
出版狀態已發佈 - 十二月 1 1974
對外發佈Yes

指紋

Combination Drug Therapy
Bone Marrow Transplantation
Cyclophosphamide
Immunosuppression
Leukemia
Bone Marrow
Transplants
Thioguanine
Chimerism
Antilymphocyte Serum
Whole-Body Irradiation
Cytarabine
Acute Myeloid Leukemia
Methotrexate
Siblings
Transplantation
Erythrocytes
Tissue Donors
Lymphocytes
Antigens

ASJC Scopus subject areas

  • Surgery
  • Transplantation

引用此文

Graw, R. G., Lohrmann, H. P., Bull, M. I., Decter, J., Herzig, G. P., Bull, J. M., ... Henderson, E. S. (1974). Bone marrow transplantation following combination chemotherapy immunosuppression (B.A.C.T.) in patients with acute leukemia. Transplantation Proceedings, 6(4), 349-354.

Bone marrow transplantation following combination chemotherapy immunosuppression (B.A.C.T.) in patients with acute leukemia. / Graw, R. G.; Lohrmann, H. P.; Bull, M. I.; Decter, J.; Herzig, G. P.; Bull, J. M.; Leventhal, B. G.; Yankee, R. A.; Herzig, R. H.; Krueger, G. R.; Bleyer, W. A.; Buja, M. L.; McGinniss, M. H.; Alter, H. J.; Whang-Peng, J.; Gralnick, H. R.; Kirkpatrick, C. H.; Henderson, E. S.

於: Transplantation Proceedings, 卷 6, 編號 4, 01.12.1974, p. 349-354.

研究成果: 雜誌貢獻文章

Graw, RG, Lohrmann, HP, Bull, MI, Decter, J, Herzig, GP, Bull, JM, Leventhal, BG, Yankee, RA, Herzig, RH, Krueger, GR, Bleyer, WA, Buja, ML, McGinniss, MH, Alter, HJ, Whang-Peng, J, Gralnick, HR, Kirkpatrick, CH & Henderson, ES 1974, 'Bone marrow transplantation following combination chemotherapy immunosuppression (B.A.C.T.) in patients with acute leukemia', Transplantation Proceedings, 卷 6, 編號 4, 頁 349-354.
Graw, R. G. ; Lohrmann, H. P. ; Bull, M. I. ; Decter, J. ; Herzig, G. P. ; Bull, J. M. ; Leventhal, B. G. ; Yankee, R. A. ; Herzig, R. H. ; Krueger, G. R. ; Bleyer, W. A. ; Buja, M. L. ; McGinniss, M. H. ; Alter, H. J. ; Whang-Peng, J. ; Gralnick, H. R. ; Kirkpatrick, C. H. ; Henderson, E. S. / Bone marrow transplantation following combination chemotherapy immunosuppression (B.A.C.T.) in patients with acute leukemia. 於: Transplantation Proceedings. 1974 ; 卷 6, 編號 4. 頁 349-354.
@article{9ced0423d5694c798d7645310b9a94fa,
title = "Bone marrow transplantation following combination chemotherapy immunosuppression (B.A.C.T.) in patients with acute leukemia",
abstract = "HL A and mixed lymphocyte culture identical sibling bone marrow can be engrafted following cyclophosphamide, total body irradiation and B.A.C.T. chemotherapy (4 day cyclophosphamide regimen in combination with 2 agents considered to be effective for treatment of acute myelocytic leukemia, cytosine arabinoside and 6 thioguanine, together with a fourth drug, bis chlorethyl nitrosurea). HL A identical bone marrow can be engrafted across the ABO erythrocyte antigen barrier. B.A.C.T. appears to provide better tumor ablation prior to marrow transplantation and sufficient immunosuppression to produce complete donor chimerism, as compared to cyclophosphamide alone. The 6 day version of the protocol may produce undesirable side effects attributable to the additional cyclophosphamide employed. Current studies in progress will examine the efficacy of the 4 day B.A.C.T. regimen in conjunction with posttransplant treatment with methotrexate for the prevention of graft vs. host disease. In situations where clinically severe graft vs. host disease occurs, patients are treated with antilymphocyte serum.",
author = "Graw, {R. G.} and Lohrmann, {H. P.} and Bull, {M. I.} and J. Decter and Herzig, {G. P.} and Bull, {J. M.} and Leventhal, {B. G.} and Yankee, {R. A.} and Herzig, {R. H.} and Krueger, {G. R.} and Bleyer, {W. A.} and Buja, {M. L.} and McGinniss, {M. H.} and Alter, {H. J.} and J. Whang-Peng and Gralnick, {H. R.} and Kirkpatrick, {C. H.} and Henderson, {E. S.}",
year = "1974",
month = "12",
day = "1",
language = "English",
volume = "6",
pages = "349--354",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Bone marrow transplantation following combination chemotherapy immunosuppression (B.A.C.T.) in patients with acute leukemia

AU - Graw, R. G.

AU - Lohrmann, H. P.

AU - Bull, M. I.

AU - Decter, J.

AU - Herzig, G. P.

AU - Bull, J. M.

AU - Leventhal, B. G.

AU - Yankee, R. A.

AU - Herzig, R. H.

AU - Krueger, G. R.

AU - Bleyer, W. A.

AU - Buja, M. L.

AU - McGinniss, M. H.

AU - Alter, H. J.

AU - Whang-Peng, J.

AU - Gralnick, H. R.

AU - Kirkpatrick, C. H.

AU - Henderson, E. S.

PY - 1974/12/1

Y1 - 1974/12/1

N2 - HL A and mixed lymphocyte culture identical sibling bone marrow can be engrafted following cyclophosphamide, total body irradiation and B.A.C.T. chemotherapy (4 day cyclophosphamide regimen in combination with 2 agents considered to be effective for treatment of acute myelocytic leukemia, cytosine arabinoside and 6 thioguanine, together with a fourth drug, bis chlorethyl nitrosurea). HL A identical bone marrow can be engrafted across the ABO erythrocyte antigen barrier. B.A.C.T. appears to provide better tumor ablation prior to marrow transplantation and sufficient immunosuppression to produce complete donor chimerism, as compared to cyclophosphamide alone. The 6 day version of the protocol may produce undesirable side effects attributable to the additional cyclophosphamide employed. Current studies in progress will examine the efficacy of the 4 day B.A.C.T. regimen in conjunction with posttransplant treatment with methotrexate for the prevention of graft vs. host disease. In situations where clinically severe graft vs. host disease occurs, patients are treated with antilymphocyte serum.

AB - HL A and mixed lymphocyte culture identical sibling bone marrow can be engrafted following cyclophosphamide, total body irradiation and B.A.C.T. chemotherapy (4 day cyclophosphamide regimen in combination with 2 agents considered to be effective for treatment of acute myelocytic leukemia, cytosine arabinoside and 6 thioguanine, together with a fourth drug, bis chlorethyl nitrosurea). HL A identical bone marrow can be engrafted across the ABO erythrocyte antigen barrier. B.A.C.T. appears to provide better tumor ablation prior to marrow transplantation and sufficient immunosuppression to produce complete donor chimerism, as compared to cyclophosphamide alone. The 6 day version of the protocol may produce undesirable side effects attributable to the additional cyclophosphamide employed. Current studies in progress will examine the efficacy of the 4 day B.A.C.T. regimen in conjunction with posttransplant treatment with methotrexate for the prevention of graft vs. host disease. In situations where clinically severe graft vs. host disease occurs, patients are treated with antilymphocyte serum.

UR - http://www.scopus.com/inward/record.url?scp=0016327519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016327519&partnerID=8YFLogxK

M3 - Article

C2 - 4155152

AN - SCOPUS:0016327519

VL - 6

SP - 349

EP - 354

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 4

ER -